EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases

Xiaokun Li, Weiqin Lu, Alexei Kharitonenkov, Yongde Luo iD

Journal of Internal Medicine · 2024-03 · 295 (3) · 292-312

DOI: 10.1111/joim.13767 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 11.01.2024. Verfasst von Xiaokun Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacological Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human fibroblast growth factor 19 (FGF19, or FGF15 in rodents) plays a central role in controlling bile acid (BA) synthesis through a negative feedback mechanism. This process involves a postprandial crosstalk between the BA‐activated ileal farnesoid X receptor and the hepatic Klotho beta (KLB) coreceptor complexed with fibrobalst growth factor receptor 4 (FGFR4) kinase. Additionally, FGF19 regulates glucose, lipid, and energy metabolism by coordinating responses from functional KLB and FGFR1‐3 receptor complexes on the periphery. Pharmacologically, native FGF19 or its analogs decrease elevated BA levels, fat content, and collateral tissue damage. This makes them effective in treating both cholestatic diseases such as primary biliary or sclerosing cholangitis (PBC or PSC) and metabolic abnormalities such as nonalcoholic steatohepatitis (NASH). However, chronic administration of FGF19 drives oncogenesis in mice by activating the FGFR4‐dependent mitogenic or hepatic regenerative pathway, which could be a concern in humans. Agents that block FGF19 or FGFR4 signaling have shown great potency in preventing FGF19‐responsive hepatocellular carcinoma (HCC) development in animal models. Recent phase 1/2 clinical trials have demonstrated promising results for several FGF19‐based agents in selectively treating patients with PBC, PSC, NASH, or HCC. This review aims to provide an update on the clinical development of both analogs and antagonists targeting the FGF19–FGFR4 signaling pathway for patients with cholestatic, metabolic, and cancer diseases. We will also analyze potential safety and mechanistic concerns that should guide future research and advanced trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseHumansMiceAnimalsFibroblast Growth FactorsSignal TransductionCarcinogenesisReceptor, Fibroblast Growth Factor, Type 4

Stichwörter der Autor:innen

FGF19FGFR4bile acidscholestasishepatocellular carcinomanonalcoholic steatohepatitis

Substanzen

Fibroblast Growth FactorsFGF19 protein, humanFGFR4 protein, humanReceptor, Fibroblast Growth Factor, Type 4

Autor:innen und Institutionen

  • School of Pharmacological Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, Texas, USA.
  • AK Biotechnologies LLC, West Palm Beach, Florida, USA.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

ORCID-Profile: Yongde Luo

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Li, X., Lu, W., Kharitonenkov, A., & Luo, Y. (2024). Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases. Journal of Internal Medicine, 295(3), 292-312. https://doi.org/10.1111/joim.13767

Vancouver

Li X, Lu W, Kharitonenkov A, Luo Y. Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases. Journal of Internal Medicine. 2024;295(3):292-312. doi:10.1111/joim.13767

BibTeX
@article{Li2024,
  author = {Li, Xiaokun and Lu, Weiqin and Kharitonenkov, Alexei and Luo, Yongde},
  title = {Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases},
  journal = {Journal of Internal Medicine},
  year = {2024},
  volume = {295},
  number = {3},
  pages = {292--312},
  doi = {10.1111/joim.13767}
}
Kostenlos starten →